These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 37391802)
1. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer. Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802 [TBL] [Abstract][Full Text] [Related]
2. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer. Cao T; Huang M; Huang X; Tang T PeerJ; 2024; 12():e16935. PubMed ID: 38435998 [TBL] [Abstract][Full Text] [Related]
3. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing. Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321 [TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer. Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064 [TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S Front Immunol; 2023; 14():1263537. PubMed ID: 37767092 [TBL] [Abstract][Full Text] [Related]
6. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355 [TBL] [Abstract][Full Text] [Related]
7. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. Sato K; Miura K; Tamori S; Akimoto K Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590 [TBL] [Abstract][Full Text] [Related]
8. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G Front Oncol; 2020; 10():1787. PubMed ID: 33042828 [No Abstract] [Full Text] [Related]
9. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer. Zhang J; Zhang M; Tian Q; Yang J Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794 [TBL] [Abstract][Full Text] [Related]
10. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy. Jiang T; Zhu J; Jiang S; Chen Z; Xu P; Gong R; Zhong C; Cheng Y; Sun X; Yi W; Yang J; Zhou W; Cheng Y Adv Sci (Weinh); 2023 Jun; 10(17):e2207257. PubMed ID: 37096846 [TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. Chen H; Pu S; Mei N; Liu X; He J; Zhang H Cancer Biomark; 2022; 35(4):379-393. PubMed ID: 36373309 [TBL] [Abstract][Full Text] [Related]
12. LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. Pan S; Wan M; Jin H; Ning R; Zhang J; Han X BMC Immunol; 2024 Jul; 25(1):42. PubMed ID: 38977952 [TBL] [Abstract][Full Text] [Related]
13. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer. Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753 [TBL] [Abstract][Full Text] [Related]
14. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478 [TBL] [Abstract][Full Text] [Related]
15. The Role of Chu J; Tang S; Li T; Fan H Front Biosci (Landmark Ed); 2024 Feb; 29(2):73. PubMed ID: 38420798 [TBL] [Abstract][Full Text] [Related]
16. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis. Zhai Q; Li H; Sun L; Yuan Y; Wang X Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620 [TBL] [Abstract][Full Text] [Related]
17. HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration. Ying B; Xu W; Nie Y; Li Y Dis Markers; 2022; 2022():8446857. PubMed ID: 36452344 [TBL] [Abstract][Full Text] [Related]
18. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447 [TBL] [Abstract][Full Text] [Related]
19. A novel fatty-acid metabolism-based classification for triple negative breast cancer. Yang X; Tang W; He Y; An H; Wang J Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837 [TBL] [Abstract][Full Text] [Related]
20. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis. Zhong G; Lou W; Shen Q; Yu K; Zheng Y Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]